Background Molnupiravir was granted emergency use authorization for the treatment of mild
to moderate coronavirus disease 2019 (COVID-19). In this study, we used population-based …

This study evaluates the association between antivirals (Molnupiravir and Nirmatrelvir-
Ritonavir) and all-cause and respiratory mortality and organ dysfunction among high-risk …

Background: In the EPIC-HR (Evaluation of Protease Inhibition for Covid-19 in High-Risk
Patients) trial, nirmatrelvir plus ritonavir led to an 89% reduction in hospitalization or death …

Background The effects of nirmatrelvir/ritonavir (NMV/r [Paxlovid]) on coronavirus disease
2019 (COVID-19) outcomes in younger vaccinated adults are unclear. The objective of this …

Introduction The randomized, placebo-controlled, double-blind MOVe-OUT trial
demonstrated molnupiravir (800 mg every 12 h for 5 days) as safe and effective for …

It is unclear whether molnupiravir has a beneficial effect on vaccinated patients infected with
the Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We …

BACKGROUND New COVID-19 oral antiviral treatments–Paxlovid (ritonavir-boosted
nirmatrelvir) 1 and Lagevrio (molnupiravir) 2–were first made available at the end of 2021 …

The efficacy of molnupiravir in treating patients with coronavirus disease 2019 (COVID‐19)
has been inconsistent across randomized controlled trials (RCTs). Thus, this meta‐analysis …

Several randomized controlled trials and real‐world cohort studies have demonstrated the
efficacies of nirmatrelvir plus ritonavir (NMV‐r) and molnupiravir (MOV) in at‐risk patients …

Importance Diabetes and COVID-19 are both global pandemics, and type 2 diabetes is a
common comorbidity in patients with acute COVID-19 and is proven to be a key determinant …